Abstract
Increased formation of advanced glycation endproducts (AGEs) constitutes a potential mechanism by which hyperglycaemia and its immediate biochemical sequelae induce micro- and macrovascular complications in diabetes. In type 1 diabetes, circulating levels of AGEs, including the major AGE Ne-(carboxymethyl)lysine (CML), have been shown to be increased and associated with the development of cardiovascular disease (CVD). In contrast, the exact role of circulating CML in type 2 diabetes (T2DM) remains unclear, because remarkably, so far no consistent data on levels of plasma CML have been described in individuals with vs. without T2DM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have